Amgen (AMGN) to Halt Discounts on Aranesp -NYTimes
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
The New York Times is reporting that Amgen (Nasdaq: AMGN) will halt pricing discounts on several of its drugs: Aranesp, Neulasta and Neupogen. According to sources, critics are saying that Amgen's rebates on its key anemia drug, Aranesp, have caused overuse of the product "at a time of mounting concerns about the product’s safety."
Amgen continues to believe that its pricing policies have not contributed to an overuse of the drug, but, "Nevertheless, we believe these contracting changes, along with other modifications, help to clear up those possible misperceptions."
Amgen has announced that the change will take effect October 1, 2008.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Amgen continues to believe that its pricing policies have not contributed to an overuse of the drug, but, "Nevertheless, we believe these contracting changes, along with other modifications, help to clear up those possible misperceptions."
Amgen has announced that the change will take effect October 1, 2008.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Ford names Dave Carroll president of Ford Energy as Lisa Drake retires
- Dolby names Marc Whitten CEO as Kevin Yeaman retires
Create E-mail Alert Related Categories
Corporate News, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
